2024
Modeling lung adenocarcinoma metastases using patient-derived organoids
Liu Y, Lankadasari M, Rosiene J, Johnson K, Zhou J, Bapat S, Chow-Tsang L, Tian H, Mastrogiacomo B, He D, Connolly J, Lengel H, Caso R, Dunne E, Fick C, Rocco G, Sihag S, Isbell J, Bott M, Li B, Lito P, Brennan C, Bilsky M, Rekhtman N, Adusumilli P, Mayo M, Imielinski M, Jones D. Modeling lung adenocarcinoma metastases using patient-derived organoids. Cell Reports Medicine 2024, 5: 101777. PMID: 39413736, PMCID: PMC11513837, DOI: 10.1016/j.xcrm.2024.101777.Peer-Reviewed Original ResearchConceptsMetastasis modelLung adenocarcinomaAutologous peripheral blood mononuclear cellsEarly-stage lung cancerMechanisms of drug resistancePeripheral blood mononuclear cellsBlood mononuclear cellsEfficacy of treatmentLung cancer metastasisLung adenocarcinoma metastasisDistant metastasisStudy clonalityAdenocarcinoma metastasisLung cancerMononuclear cellsDrug resistanceMetastasisSuppress metastasisIndividual patientsTumor evolutionCancer metastasisHuman metastasesPatientsBiological featuresRNA sequencing
2016
Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics
Collins D, Sundar R, Lim J, Yap T. Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics. Trends In Pharmacological Sciences 2016, 38: 25-40. PMID: 27871777, DOI: 10.1016/j.tips.2016.10.012.Peer-Reviewed Educational MaterialsConceptsPrecision medicineNext-generation sequencingMechanisms of drug resistanceField of immunotherapyManagement of cancer patientsOptimize treatment efficacyAntitumor responseIntertumoral heterogeneityClonal evolutionTargeted agentsMinimal toxicityDrug resistanceCancer patientsTreatment efficacyBiomarker developmentBiomarker discoveryCancer researchCancerCompounds promisesImmunotherapyMedicine
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply